Expanded cryopreserved mesenchymal stromal cells as an optimal source for graft-versus-host disease treatment

Biologicals

Volumn 42, Issue 3, 2014, Pages 139-144

  Holubova, Monika ^a   Lysak, Daniel ^a   Vlas, Tomas ^a   Vannucci, Luca ^b   Jindra, Pavel ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF MATHEMATICS   (Czech Republic)

^c Czech National Marrow Donors Registry   (Czech Republic)

Author keywords

Cryopreservation; Immunomodulation; Mesenchymal stromal cells

Indexed keywords

5' NUCLEOTIDASE; CD14 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD69 ANTIGEN; ENDOGLIN; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; MICROSOMAL AMINOPEPTIDASE; THY 1 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL METABOLISM; CELL PROLIFERATION; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; CRYOPRESERVATION; DOWN REGULATION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMA CELL; MITOSIS INHIBITION; MOLECULAR DYNAMICS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; THAWING; CYTOLOGY; GRAFT VS HOST DISEASE;

CELL PROLIFERATION; CRYOPRESERVATION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS;

EID: 84900986769     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2014.01.003     Document Type: Article

References (38)

1. Friedenstein A.J., Gorskaja J.F., Kulagina N.N. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol 1976, 4:267-274.
2. Zuk P.A., Zhu M., Mizuno H., Huang J., Futrell J.W., Katz A.J., et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001, 7:211-228.
3. Akimoto K., Kimura K., Nagano M., Takano S., To'a Salazar G., Yamashita T., et al. Umbilical cord blood-derived mesenchymal stem cells inhibit, but adipose tissue-derived mesenchymal stem cells promote glioblastoma multiforme proliferation. Stem Cells Dev 2013, 22:1370-1386.
4. Perry B.C., Zhou D., Wu X., Yang F.C., Byers M.A., Chu T.M., et al. Collection, cryopreservation, and characterization of human dental pulp-derived mesenchymal stem cells for banking and clinical use. Tissue Eng Part C Methods 2008, 14:149-156.
5. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006, 8:315-317.
6. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
7. Lei Z., Yongda L., Jun M., Yingyu S., Shaoju Z., Xinwen Z., et al. Culture and neural differentiation of rat bone marrow mesenchymal stem cells in vitro. Cell Biol Int 2007, 31:916-923.
8. Bassi E.J., Aita C.A., Camara N.O. Immune regulatory properties of multipotent mesenchymal stromal cells: where do we stand?. World J Stem Cells 2011, 3:1-8.
9. Kode J.A., Mukherjee S., Joglekar M.V., Hardikar A.A. Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration. Cytotherapy 2009, 11:377-391.
10. Augello A., Tasso R., Negrini S.M., Amateis A., Indiveri F., Cancedda R., et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005, 35:1482-1490.
11. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
12. Meisel R., Zibert A., Laryea M., Gobel U., Daubener W., Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621.
13. Zheng Z.H., Li X.Y., Ding J., Jia J.F., Zhu P. Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagen-reactive T cells in rheumatoid arthritis. Rheumatol (Oxford) 2008, 47:22-30.
14. Dazzi F., Krampera M. Mesenchymal stem cells and autoimmune diseases. Best Pract Res Clin Haematol 2011, 24:49-57.
15. Dalal J., Gandy K., Domen J. Role of mesenchymal stem cell therapy in crohn's disease. Pediatr Res 2012, 71:445-451.
16. Toubai T., Paczesny S., Shono Y., Tanaka J., Lowler K.P., Malter C.T., et al. Mesenchymal stem cells for treatment and prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation. Curr Stem Cell Res Ther 2009, 4:252-259.
17. Thirumala S., Gimble J.M., Devireddy R.V. Evaluation of methylcellulose and dimethyl sulfoxide as the cryoprotectants in a serum-free freezing media for cryopreservation of adipose-derived adult stem cells. Stem Cells Dev 2010, 19:513-522.
18. Pasch J., Schiefer A., Heschel I., Rau G. Cryopreservation of keratinocytes in a monolayer. Cryobiology 1999, 39:158-168.
19. Balci D., Can A. The assessment of cryopreservation conditions for human umbilical cord stroma-derived mesenchymal stem cells towards a potential use for stem cell banking. Curr Stem Cell Res Ther 2013, 8:60-72.
20. Miranda-Sayago J.M., Fernandez-Arcas N., Benito C., Reyes-Engel A., Herrero J.R., Alonso A. Evaluation of a low cost cryopreservation system on the biology of human amniotic fluid-derived mesenchymal stromal cells. Cryobiology 2012, 64:160-166.
21. Kebriaei P., Isola L., Bahceci E., Holland K., Rowley S., Mcguirk J., et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009, 15:804-811.
22. Fang B., Song Y., Liao L., Zhang Y., Zhao R.C. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant Proc 2007, 39:3358-3362.
23. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
24. Le Blanc K., Rasmusson I., Sundberg B., Götherström C., Hassan M., Uzunel M., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
25. von Bonin M., Stölzel F., Goedecke A., Richter K., Wuschek N., Hölig K., et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009, 43:245-251.
26. Francois M., Copland I.B., Yuan S., Romieu-Mourez R., Waller E.K., Galipeau J. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-gamma licensing. Cytotherapy 2012, 14:147-152.
27. Vosganian G.S., Waalen J., Kim K., Jhatakia S., Schram E., Lee T., et al. Effects of long-term cryopreservation on peripheral blood progenitor cells. Cytotherapy 2012, 14:1228-1234.
28. Baust J.M., Van Buskirk R., Baust J.G. Modulation of the cryopreservation cap: elevated survival with reduced dimethyl sulfoxide concentration. Cryobiology 2002, 45:97-108.
29. Owen R.E., Sinclair E., Emu B., Heitman J.W., Hirschkorn D.F., Epling C.L., et al. Loss of T cell responses following long-term cryopreservation. J Immunol Methods 2007, 326:93-115.
30. Haack-Sorensen M., Bindslev L., Mortensen S., Friis T., Kastrup J. The influence of freezing and storage on the characteristics and functions of human mesenchymal stromal cells isolated for clinical use. Cytotherapy 2007, 9:328-337.
31. de Lima Prata K., de Santis G.C., Orellana M.D., Palma P.V., Brassesco M.S., Covas D.T. Cryopreservation of umbilical cord mesenchymal cells in xenofree conditions. Cytotherapy 2012, 14:694-700.
32. Casado-Díaz A., Santiago-Mora R., Jiménez R., Caballero-Villarraso J., Herrera C., Torres A., et al. Cryopreserved human bone marrow mononuclear cells as a source of mesenchymal stromal cells: application in osteoporosis research. Cytotherapy 2008, 10:460-468.
33. Shen J.L., Huang Y.Z., Xu S.X., Zheng P.H., Yin W.J., Cen J., et al. Effectiveness of human mesenchymal stem cells derived from bone marrow cryopreserved for 23-25 years. Cryobiology 2012, 64:167-175.
34. Xiang Y., Zheng Q., Jia B.B., Huang G.P., Xu Y.L., Wang J.F., et al. Ex vivo expansion and pluripotential differentiation of cryopreserved human bone marrow mesenchymal stem cells. J Zhejiang Univ Sci B 2007, 8:136-146.
35. Ginis I., Grinblat B., Shirvan M.H. Evaluation of bone marrow-derived mesenchymal stem cells after cryopreservation and hypothermic storage in clinically safe medium. Tissue Eng Part C Methods 2012, 18:453-463.
36. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
37. Le Blanc K., Rasmusson I., Götherström C., Seidel C., Sundberg B., Sundin M., et al. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol 2004, 60:307-315.
38. Muller I., Kordowich S., Holzwarth C., Isensee G., Lang P., Neunhoeffer F., et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis 2008, 40:25-32.